Bacteremia Due to Oral Viridans Streptococci in Neutropenic Patients with Cancer: Cytostatics Are a More Important Risk Factor than Antibacterial Prophylaxis
Sir-In their recent article Bochud et al. [1] stated that "the fluoroquinolones are frequently used as prophylaxis for patients with cancer . . . and bacteremia due to these microorganisms has been observed under this prophylactic regimen." They also stated that the problem o f viridans streptococcal bacteremia . . is probably related to the use of quinolones as antibacte rial prophylaxis." However, the references chosen to support these statements were incorrect since Cohen et al. [2] and Henslee et al. [3] reported that bacteremia developed exclusively while the patients were receiving co-trimoxazole prophylaxis, which was also the antimicrobial given to most o f the patients described by Weisman et al. [4] and Elting et al. [5] .
During 1986-1989, bacteremia due to oral viridans strepto cocci (OVS) developed in 94 (28%) of 341 neutropenic episodes that occurred in adults treated for hematologic malignancies at our center. Although both ciprofloxacin and co-trimoxazole plus colistin had been given as prophylaxis, bone marrow trans plant (BMT) recipients had all been given ciprofloxacin (table  1) rates of bacteremia, even after administration of the higher dose of cytarabine, were still markedly lower than that (56%) for 99 allogeneic BMT recipients during the same period (P < .001).
This remarkably high rate was attributed to the occurrence of severe oromucositis as a result of using the more-intensive con ditioning regimen that included anthracyclines, particularly idarubicin [6] , in conjunction with total body irradiation and cyclophosphamide [7] . Those patients who underwent condi tioning for transplantation without additional anthracyclines ex perienced a rate of OVS bacteremia similar to that for patients treated with cytarabine {">1 g/[m2 • d]). Thus, the higher dose of cytarabine and, moreover, the use of idarubicin had a much greater influence on the development of OVS bacteremia than did the prophylactic regimen. Only when lower doses of cytara bine or other cytostatics were used did the negative impact of ciprofloxacin prophylaxis become clearer.
It is also of interest that the majority of strains that were iso lated from BMT recipients and that could be adequately identi fied to the species level with use of the API Strep system protracted oromucositis in BMT recipients [7, 9] that is of quite a different character than the milder form induced by cytarabine. In contrast, high doses of cytarabine can be profoundly toxic to the gut and lungs [ 10] . The colonization of the stomach or digestive tract might therefore provide the alternative portal o f entry that Bochud and colleagues suggested. Extensive colon ization of the stomach and the small intestine would also be facilitated by any H2 antagonists used to manage the dyspepsia that frequently occurs following cytostatic chemotherapy. The use of these agents was also implicated by Elting and associates [5] as a significant risk factor for the development of the so-called alpha strep shock syndrome. Moreover, patients with oromucositis tend to swallow large volumes of slimy mucus, which may assist in protecting the oral streptococci. Therefore, the presence of gastrointestinal colonization in pa tients with bacteremia due to S. mitis might explain why only a minority of these patients go on to develop the alpha strep shock syndrome; the microbial load may well be sufficient to elicit the release of cytokines that are necessary to induce sepsis syn drome, adult respiratory distress syndrome, and, in some cases, fatal multiorgan failure.
Reply
Sir-We agree with Donnelly et al. that bacteremia due to oral viridans streptococci (OVS) in neutropenic patients with cancer has occurred not only while the patients were receiving prophy laxis with fluoroquinolones but also while they were receiving other prophylactic antibiotic regimens. This finding was inad vertently omitted in our text but cited in the references. The interesting data of Donnelly et al. as well as data from other centers, including ours, clearly suggest that aggressive cytostatic chemotherapy is probably the key factor predisposing neutro penic patients to OVS bacteremia. However, it appears clear that several widely used prophylactic agents, including fluoro quinolones and co-trimoxazole, are not effective in preventing OVS bacteremia. Moreover, OVS bacteremia was practically un known before the use of these prophylactic regimens, and two case-control studies have shown an association between the use ofquinolones or co-trimoxazole and the occurrence of OVS bac teremia [1, 2] . Thus, certain prophylactic antibiotics may not only be ineffective in preventing OVS bacteremia, but they may also alter the endogenous bacterial flora in a way that predis poses susceptible patients to the infection.
